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Regulatory frameworkAbstract Seven years after the launch of the European Paediatric Medicine Regulation, lim-
ited progress in paediatric oncology drug development remains a major concern amongst
stakeholders – academics, industry, regulatory authorities, parents, patients and caregivers.
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Plan
Precompetitive
development
Long-term follow upregulatory pressure to propose early Paediatric Investigation Plans (PIPs), missed opportuni-
ties to explore new drugs potentially relevant for paediatric malignancies, lack of innovative
trial designs and no new incentives to develop drugs against speciﬁc paediatric targets are
some unmet needs. Better access to new anti-cancer drugs for paediatric clinical studies and
improved collaboration between stakeholders are essential. The Cancer Drug Development
Forum (CDDF), previously Biotherapy Development Association (BDA), with Innovative
Therapy for Children with Cancer Consortium (ITCC), European Society for Paediatric
Oncology (SIOPE) and European Network for Cancer Research in Children and Adolescents
(ENCCA) has created a unique Paediatric Oncology Platform, involving multiple stakehold-
ers and the European Union (EU) Commission, with an urgent remit to improve paediatric
oncology drug development. The Paediatric Oncology Platform proposes to recommend
immediate changes in the implementation of the Regulation and set the framework for its
2017 revision; initiatives to incentivise drug development against speciﬁc paediatric oncology
targets, and repositioning of drugs not developed in adults. Underpinning these changes is a
strategy for mechanism of action and biology driven selection and prioritisation of potential
paediatric indications rather than the current process based on adult cancer indications.
Pre-competitive research and drug prioritisation, early portfolio evaluation, cross-industry
cooperation and multi-compound/sponsor trials are being explored, from which guidance
for innovative trial designs will be provided.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Childhood and adolescent cancers remain a major
cause of morbidity, mortality and social concern in Eur-
ope [1–3] with 3000 children and adolescents dying of
cancer each year [4]. In the developed world, although
80% of children survive cancer, they may suﬀer long-
term eﬀects from their treatment [5] and approximately
20% of patients will die of their disease or of disease-
related causes; as such paediatric cancer remains the
number one non-accidental cause of death in children
and adolescents [6]. Improvements to all standards of
paediatric cancer care and a focus on incurable diseases
are urgently needed, entailing fresh approaches to the
many complex aspects of treating childhood cancers,
including faster introduction of new medicines for chil-
dren into front-line care, innovations in study design
and drug development and collaboration between stake-
holders. Additionally, as new drugs are introduced, it is
imperative for childhood cancer survivors to have long-
term follow up (LTFU) into adulthood to collect data
on the later eﬀects of childhood treatment for cancer [2].
The European Paediatric Regulation [7] provides the
regulatory framework for drug development for children
and adolescents with cancer. It aims to increase avail-
ability of authorised medicines for children through gen-
eration of safety and eﬃcacy data and high-quality
ethical paediatric clinical research, and to produce better
information on paediatric medicines, in general. Over-
coming oﬀ-label use by developing and making available
new, age-appropriate paediatric medicines is also within
the Regulation’s remit.
The Paediatric Regulation stipulates that pharmaceu-
tical companies propose and comply with a Paediatric
Investigation Plan (PIP) before seeking marketingauthorisation (MA) for a new medicine (or variation
of an existing MA). Completed PIPs are rewarded with
a six-month extension of the medicine’s Supplementary
Protection Certiﬁcate (SPC) or, in the case of orphan-
designated medicines, a 2-year extension of the 10-year
market exclusivity for the authorised indication.
Despite signiﬁcant changes in paediatric oncology
drug development in the years after the Regulation came
into force in 2007 and an increase in the total number of
PIPs ﬁled, frustration remains amongst all stakeholders
at the seemingly slow speed of progress [8]. The lack of a
uniﬁed driving force to facilitate coherent actions for
further change and progress has become apparent. A
lack of increase in early phase paediatric oncology trials
in Europe compared with the United States (US), grow-
ing regulatory requirement to propose PIPs early in
drug development, missed opportunities to explore eﬃ-
cient drugs in development for adults that may be rele-
vant for paediatric malignancies, lack of innovation in
trial designs and limited incentives to develop drugs
against speciﬁc paediatric targets continue to be areas
of signiﬁcant concern for paediatric drug developers
across academia, industry, regulatory authorities, and
importantly, amongst patients, parents and caregivers.
To address these concerns and promote progress,
two-yearly Paediatric Oncology Workshops were initi-
ated in 2011 by the Cancer Drug Development Forum
(CDDF, previously the Biotherapy Development Asso-
ciation (BDA)) along with the European consortium
for Innovative Therapies for Children with Cancer
(ITCC), and the European Society for Paediatric Oncol-
ogy (SIOP Europe) [1], within the framework of the
European Network for Cancer Research in Children
and Adolescents (ENCCA). The ITCC consortium was
created in 2003 to develop early evaluation of new
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lence awarded funding for 2011–2015, in the European
7th Framework Programme (FP), to structure and
enhance collaboration in clinical and translational
research in European paediatric oncology.
The 2011 BDA/CDDF Workshop identiﬁed sectors
within paediatric oncology drug development for action
and speciﬁc strategies to improve upon and speed drug
development and despite methodological challenges,
between 2011 and 2013 some improvements to paediat-
ric cancer drug development were made. The second
workshop in 2013 examined paediatric cancer drug
development progress, or more speciﬁcally lack thereof,
and sought input from all stakeholders on the means to
enact needed changes. The need to create a Paediatric
Oncology Platform to enable all stakeholders to work
together to improve current implementation of the Reg-
ulation was made clear, as was the need to identify
where changes may most usefully be made to the Regu-
lation at the time of its review in 2017.2. Landscape, needs and progress (2011–2013)
2.1. Regulation
Pharmaceutical companies are regulated by the legal
framework Eudralex, a 10-volume collection of regula-
tions governing medicinal products for public health
needs in the EU. The Paediatric Regulation aims to
make medicines for cancer and other diseases available
in Europe for children [7]. The European Medicines
Agency (EMA) operates within this framework. Secur-
ing authorisation for oncology drugs requires extensive
assessment of data on quality, eﬃcacy and safety. In
oncology drug development, data are often not
suﬃciently robust and failure late in development is a
particular risk due to early studies not being predictive
and target populations not well identiﬁed. Such chal-
lenges are even greater for paediatric oncology medicine
development because often less is known about these
new medicines and their eﬀects on paediatric cancer,
both pre-clinically and in the clinic and rarely are
exploratory studies performed in children before a clear
beneﬁt-risk relationship has been established in adults.
Within the EMA, the Paediatric Committee (PDCO)
is responsible for agreement of PIPs proposed by the
sponsoring pharmaceutical company. PIPs include com-
prehensive study plans aimed at generating age-appro-
priate safety and tolerability, pharmacokinetic (PK)
and, potentially, eﬃcacy data for MAs of medicines
for speciﬁc indications in children. Each MA for an
adult indication (e.g. treatment of breast cancer)
requires an agreed PIP covering the same condition,
and/or a waiver for clinical studies where there is no
opportunity for a paediatric indication. Waivers can
be granted on three speciﬁc grounds – the product islikely ineﬀective or unsafe, the condition or disease does
not occur in children, or the product does not represent
a signiﬁcant beneﬁt over existing treatment. As a result,
the opportunity to study innovative anti-cancer medi-
cines in children is diﬃcult.
In 2012, the Commission reported that in general
there had been improvement in the development process
for paediatric medicines since 2007 [10]. However, this
was not true for paediatric oncology where expectations
for PIPs had not been met [8]; while the number of sub-
mitted PIPs had increased overall, successful completion
had not always followed. Although the PDCO can
review and agree to the original requirements of a PIP,
modiﬁcations often follow as additional adult data are
acquired during development, resulting in terminated
development programmes, and modiﬁed PIPs. In part
due to this there have been half as many modiﬁed PIPs
as new PIPs. This again highlights the challenges faced
in paediatric oncology drug development, which is per-
ceived as dependent upon adult indications.
In addition, regulators are aware that the current Reg-
ulation does not yet fully cover the public health needs of
paediatric oncology due to the mismatch between the
conventional adult-centred drug development pro-
grammes and the urgent medical need in taxonomically
unrelated paediatric malignancies. Work is ongoing to
develop a more relevant framework for paediatric oncol-
ogy PIPs based on a drug’s mechanism of action (MoA)
rather than the adult indication, particularly where a
drug is used in adult oncology and where there is evi-
dence for use in children with as yet unmet needs.
Encouragingly several companies have already proposed
such MoA driven PIPs on a voluntary basis.
Finally in 2011, the European Network of Paediatric
Research at the EMA initiative (EnprEMA) was
established to facilitate communication between acade-
mia and the EMA enabling paediatric groups to share
knowledge and best practice. Enhanced communication
between the EMA and the Federal Drug Agency (FDA)
also contributed to better overall communications. There
was simpliﬁcation of some administrative regulatory
requirements and a small increase in the number of PIPs
in oncology, but the pace of change continues to be too
slow.
2.2. Academia
While survival for childhood cancers has improved
steadily since 1960, as of 2000 the decrease in mortality
has reached a plateau. For children with poor-prognosis
cancers resistant or refractory to conventional treatment,
overall survival is less than 25%. High-risk leukaemias,
high-risk neuroblastomas, metastatic sarcomas,
high-grade gliomas and high-risk medulloblastomas are
the most common paediatric cancers with poor outcomes
[11–17]. Improvements in survival for children with these
diseases have lagged behind other malignancies, and with
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have increased leading to chronic and disabling morbid-
ities [18,19].
Despite successful development of molecularly tar-
geted therapeutics in adults over the last decade, rela-
tively few such studies have been completed in
paediatric oncology, highlighting an unmet need in this
area. Further progress in this ﬁeld suggests clinical trials
driven by biological hypotheses result in higher numbers
of drugs reaching the bedside [20,21], but this has not yet
translated into improvements within paediatric oncol-
ogy drug development.
From 2007 to mid-2012, 45 PIPs were approved in
oncology for the central nervous system (CNS), leukae-
mia, lymphoma, solid tumours and supportive care, but
none have included the most aggressive of childhood
cancers such as high-risk neuroblastoma [22]. This is
because creation of PIPs has been driven by the relevant
adult indication; regulatory obligations for paediatric
development for a number of drugs with potential for
childhood cancers were waived, as noted above, despite
the fact that the MoA may have been shown to be bio-
logically relevant in a speciﬁc paediatric cancer.
Since 2007 the number of drugs in early phase trials
being run by the ITCC has grown from one in 2007 to
12 in 2013, with half the trials being conducted to com-
ply with the regulatory requirements of a PIP [23–28].
The New Drug Development Strategy (NDDS) project
run by ITCC and ENCCA continues to deﬁne strategies
for speciﬁc malignancies. However, of 28 non-generic
oncology drugs approved since 2007, of which 26 were
potentially relevant for paediatric malignancies based
on MoA, 50% of them were waived [22].
For the academic community, frustration continues
in the lack of early access to new drugs for preclinical
and early clinical trials, the diﬃculty of organising,
funding and conducting academic-led trials, and the
challenge of managing PIPs. A development programme
in an adult disease should not be the only valid guide to
paediatric oncology drug development, and paediatric
development should instead clearly be guided by the
biology of the malignancy and the MoA of the drug.
Only then will true beneﬁt again be able to be seen in
paediatric cancer drug development.2.3. Industry
As PIP requirements become more stringent, sponsor-
ing pharmaceutical companies have invested more time
and resource to develop and execute them; speciﬁcally
because of the numerous PIP modiﬁcations noted above,
this process is often long-term, and delivery of a success-
ful PIP is often seen as ‘at risk’. Multiple PIPs in the same
area of development, for example, within a similar diagno-
sis or tumour type may be required, and make recruitment
to required clinical studies and subsequent successful PIPexecution extremely diﬃcult. There is also a lack of clar-
ity on the procedure regarding the compliance check at
the ﬁnalisation of the PIP. For small organisations, such
as biotechnology companies and so-called ‘start-ups’, the
increasing cost of paediatric development can be prohib-
itive despite the long-term incentives oﬀered by the Pae-
diatric Regulation, and the PIP opportunity is often
unclear, or lost with these early phase compounds, as
the ultimate fate of many molecules in development by
biotechnology companies is unknown to their sponsor.
Additional, signiﬁcant challenges are posed by dis-
crepancies between US and European requirements, as
well as by diﬀerences in timelines for paediatric drug
development. Numerous delays have been identiﬁed
around PIPs which, while a European legal requirement,
have global implications. Although there are similar but
not identical legal requirements in the United States, the
mismatch between PDCO requirements, academic rec-
ommendations and US and EU agencies has led to con-
siderable challenges for industry, where the drive to
paediatric development may be rare or absent, and bal-
ance, greater ﬂexibility of process and collaborative ven-
ture are essential to the success of a paediatric
programme. Greater clarity, and more importantly syn-
ergy between legislative regulations may improve the
ability of industry to deliver a singular, succinct paediat-
ric oncology drug development plan to time and quality.2.4. Parents, patients and patient advocates
For parents and patient advocates there are aspects
of paediatric oncology drug development that are unpal-
atable and unacceptable. The lack of options through
early phase trials for patients with relapsed malignancy
and painfully slow progress in bringing new drugs into
front-line therapy are very major concerns. Financial
limitations within the pharmaceutical industry and reg-
ulatory hurdles within EMA are perceived as a hin-
drance to an increase in paediatric trials and a cause
of major delays in the development of speciﬁc drugs
for children. The disparity between US and EU paediat-
ric drug development due to the lack of centralised fund-
ing in Europe and poor coordination between EMA and
FDA on the authorisation process is an enormous frus-
tration and leads, each year, to parents taking their chil-
dren to the US for treatment that is unavailable in
Europe; this is both an emotional and ﬁnancial cost to
families and a cause of inequality of treatment. Parents
and patient advocates see paediatric drug development
as a social responsibility and the perceived lack of drive
for change and lack of ﬂexibility in the system is a cause
of frustration.
Meanwhile, there is recognition that patient advocacy
groups could achieve more through better focussed col-
laboration in the ﬁeld of lobbying regulators, sponsors,
politicians and policy makers, and in fundraising. The
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of America (USA) by the mother of a child who did not
survive cancer, provides a transferable incentive to spon-
soring pharmaceutical companies – an FDA priority
review voucher – and shows what is possible with direc-
ted partnership [29].3. 2014–2017 focus
Until the opportunity comes in 2017 to revise the cur-
rent Regulation, further developments and initiatives
must take place within its conﬁnes and should act as a
force for change to guide forthcoming modiﬁcations.
Speciﬁc areas have been identiﬁed and are summarised
in Table 1. Some of this work has already begun through
the ITCC and ENCCA’s New Drug DevelopmentTable 1
Proposed initiatives and actions.
Improving early access to new anticancer drugs for children and adolescents
1. Improve access to compounds for preclinical testing and biological stu
2. Increase the number of drugs in early phase trials signiﬁcantly
3. Consider running early phase trials before submitting a Paediatric Inve
4. Consider accrual of adolescents in adult phase 1 and 2 trials when scie
5. Emulate the National Cancer Institute (NCI) clinical trial funding and
6. Work to de-risk the perception of paediatric studies and create value i
7. Simplify the process for initiation of a PIP proposal and enforce acade
Prioritising oncology compounds for development in children/adolescents wit
1. Develop a strategy for selection and prioritisation of drugs for paediat
than the current process based on adult cancer indications
2. Increase our understanding of molecular pathways and key drivers wh
3. Set up disease focus groups: academic tumour groups must identify ke
work, and deﬁne a strategy for each disease based on current treatmen
4. Consider paediatric oncology drug development as pre-competitive res
5. Set up early cross-portfolio evaluation, including academic investigator
6. Implement cross-pharmaceutical company discussion that will facilitate
7. Develop multi-compound, multi-company trials to speed up evaluation
8. Set up better incentives tailored to risks taken and commitments made b
paediatric drugs
Facilitating cooperation and collaboration between all stakeholders
1. Achieve better academia-industry communication with improved trust a
link with industry and have global harmonised opinions
2. Encourage four-party discussions and drug-prioritisation meetings
3. Broaden collaborative links between clinicians, scientists, European Me
patient organisations: the Cancer Drug Development Forum (CDDF)-I
European Network for Cancer Research in Children and Adolescents (E
diatric Oncology Platform
4. Set up an annual international working meeting with all stakeholders to
action plans
5. Link with initiatives in North America and worldwide
6. Include the European Commission
7. Prepare the proposals for revision of the Paediatric Regulation in 2017
Setting-up long-term follow-up (LTFU) of children and adolescents exposed
1. Set up LTFU that is patient-centred and performed in academic centre
2. Deﬁne LTFU so that data can be shared with regulatory authorities fo
3. Build a joint programme and partnership between academia and indus
4. Use the concept of Survivorship Passport and empower survivors as p
5. Implement LTFU on extension studies, with post-marketing surveillan
6. Perform large, joint – academic and industry – randomised trials and t
7. Consider cross-pharmaceutical company initiativesStrategy (NDDS) programme, which is integrating basic,
translational and clinical research into guidelines for
drug development for each paediatric cancer and will
provide expertise to regulators and pharmaceutical com-
panies. Additionally, the NDDS disease focus groups
bring together clinicians, researchers, statisticians, regu-
lators, PDCO members and EMA’s Paediatric Oncology
Task Force, enabling academics and EMA/PDCO par-
ticipants to share and address topics in oncology drug
development.4. The CDDF-ITCC-ENCCA-SIOPE Paediatric
Oncology Platform
The Platform comprises four Working Groups
each made up of members from all stakeholder groupsin Europe
dies
stigation Plan (PIP)
ntiﬁcally and medically relevant
programming model in Europe
n paediatric oncology
mic participation in this
h cancer
ric development based on biology and mechanism of action rather
ich are relevant for paediatric tumours
y contacts, review existing data on tumour biology and preclinical
t options
earch
s and paediatric oncology networks
drug selection and prioritisation
and spread risk and cost
y pharmaceutical companies, as well as for development of speciﬁc
nd conﬁdence. Academic groups to identify global leaders who will
dicines Agency (EMA)/Paediatric Committee (PDCO) and parent/
nnovative Therapy for Children with Cancer Consortium (ITCC)-
NCCA)- European Society for Paediatric Oncology (SIOPE) Pae-
update and share, address issues, propose solutions and elaborate
to new drugs
s
r continuous monitoring of beneﬁt-risk
try
artners of LTFU research
ce and risk management plans
ransfer LTFU to sustainable academic platforms
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advocates – and led by a stakeholder appropriate to
the speciﬁc priority of that group:
4.1. MoA and biology-driven drug development within the
current regulation
Academia led: To deﬁne a strategy and process for the
implementation of MoA and biology-driven drug
development and deliver precision medicine within the
current regulation; (i.e. to drive the inclusion of patients
into early drug trials through molecular proﬁling of
their tumour).
4.2. Compound prioritisation across industry
Industry led: To address prioritisation of drugs within
pipelines across companies (especially where several
companies are developing drugs against the same target)
and deﬁne how best to implement multi-compound/
multi-company trials.
4.3. Innovative design and methodology for drug
development
Including better extrapolation from adult data – EMA
and PDCO led: To propose methodology guidance to
accelerate paediatric drug development with consider-
ation of current challenges: drugs used at their optimal
biological dose; use of biomarkers; the challenge of the
extreme rarity of paediatric patients with a biomarker-
deﬁned malignancy; and concomitant evaluation of
eﬃcacy and toxicity.
4.4. New incentives for speciﬁc paediatric drugs and drug
repositioning
Parents/patient advocate led: To propose new EU reg-
ulatory initiatives to better incentivise drug development
for life-threatening paediatric diseases; e.g. oncology
drugs against speciﬁc paediatric biological targets (e.g.
N-MYC in neuroblastoma) or drugs failing in adults
to be repositioned for paediatric diseases.
The CDDF-ITCC-ENCCA-SIOPE Paediatric Oncol-
ogy Platform will meet annually to monitor progress.
5. Conclusion
The CDDF-ITCC-ENCCA-SIOPE Paediatric Oncol-
ogy Platform, a unique collaboration of academia,
industry, patient advocates and regulatory authorities,
has been formed to harness the energies of these
stakeholder groups for their common purpose and most
importantly to provide the drive for change in paediatric
oncology drug development. The goal is to rapidly and
eﬃciently evaluate and prioritise new anti-cancer drugsin children with cancer and to advance those with prom-
ise quickly into front-line therapy. For now this will be
carried out within the conﬁnes of the current European
Paediatric Regulation, but with a view to providing the
framework for essential revisions to the Regulation in
2017. By strengthening cooperation through understand-
ing and working with the problems faced by each stake-
holder group, and through a determination to work
cooperatively for the future of children with cancer, the
Platform aims to achieve concrete results in paediatric
oncology drug development.Conﬂict of interest statement
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